Prestige Consumer Healthcare stock
PBHNYSEPrestige Consumer Healthcare Inc., HealthcareISIN US74112D1019
54Score 54 out of 100, Neutral
Price and trend
33 / 100
Price history
−25% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 15% below it.
Since July 2025 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 44).
The price is 35% below its 52-week high. Largest decline in 20 years: 70% (July 2007 to March 2009).
Chart figures for advanced users
- SMA 50$47.53
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$53.23
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)44
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$42.98
- The lowest closing price of the last twelve months.
- Resistance$70.21
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Prestige Consumer Healthcare Inc. belongs to the Medical (Pharmaceuticals) industry (United States) and, with a market value of $2.15B, is number 14 of 17 companies in its industry on MEQIRI.
- In fiscal 2026 it reported revenue of $1.09B (down 4.3% year on year) and earnings of $190.3M (down 11.3%).
- For fiscal 2027, analysts expect on average revenue of $1.3B (up 19.2%) and adjusted earnings per share of $4.58 (up 4.4%).
Show more
- MEQIRI Score 54 out of 100 (Neutral): rank 347 of 714 in Healthcare, median 53.
- The P/E is 13.9 (Medical (Pharmaceuticals) median 35.1, own median of recent years 14.3).
- Our model puts fair value at $94.14, with the price 53% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Below fair valuePrice 53% below the fair value of $94.14.Valuation 80
- Earnings turn into cashFree cash flow 138% of earnings over the last 12 months.Fundamentals 76
Weaknesses
- High debtDebt 1.09 times equity (latest quarter), Medical (Pharmaceuticals) median 0.29.Stability 68
Its standout strengths are valuation and fundamentals, while technical analysis and momentum hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 55 to 54.
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- price far below its 52-week high
- weak momentum
Valuation
Valuation signal
Significantly undervaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $72.41 and expensive above $134.48 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $73.99 (cash-flow model) and $114.29 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 9.8%. At 10.8% the fair value would be $88.98, at 8.8% it would be $101.35.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (35.1).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 5.1% on the twelve months before. Revenue has grown solidly since 2007, at about 7% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 53%, operating 28%, net 17%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 4 Feb 2027in 84 days
- Last reported
- 5 Nov 2026EPS reported $1.13 (expected $1.07)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $4.580.0%
- Revenue
- $1.3B0.0%
- Earnings per share
- $5.130.0%
- Revenue
- $1.38B0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +3.5%Fiscal 2027 revenue guidance raised to $1.29 billion to $1.315 billion entirely because of acquisitions; organic growth of 1% to 3% is unchanged.
“For fiscal '27, we now expect revenues of $1.29 billion to $1.315 billion, while maintaining our expectation for organic revenue growth of 1% to 3%, unchanged from our prior outlook.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 Aug 2026 (fiscal Q1 2027), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
- Zerillo JeffreySale
11 May 2026, Senior VP Operations
- Shares
- 351
- Price
- $52.28
- Value
- $18,350
- Zerillo JeffreySale
7 May 2026, Senior VP Operations
- Shares
- 305
- Price
- $54.36
- Value
- $16,580
- Zerillo JeffreySale
5 May 2026, Senior VP Operations
- Shares
- 1,207
- Price
- $54.99
- Value
- $66,373
Show 5 more
- Zerillo JeffreySale
5 May 2026, Senior VP Operations
- Shares
- 346
- Price
- $55.32
- Value
- $19,141
- Zerillo JeffreySale
11 Feb 2026, Senior VP Operations
- Shares
- 1,000
- Price
- $65.93
- Value
- $65,930
- Zerillo JeffreySale
1 Dec 2025, Senior VP Operations
- Shares
- 281
- Price
- $60.00
- Value
- $16,860
- Zerillo JeffreySale
28 Nov 2025, Senior VP Operations
- Shares
- 719
- Price
- $60.00
- Value
- $43,140
- Byom John ESale
25 Nov 2025, Board
- Shares
- 3,000
- Price
- $59.35
- Value
- $178,050
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Prestige Consumer Healthcare
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 54
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Pharmaceuticals)
The next larger and next smaller companies by market value
- Tsuruha Holdings3391.T $7B62
- MatsukiyoCocokara3088.T $6.63B74
- Abbott IndiaABBOTINDIA.NS $5.92B74
- Beijing Tongrentang600085.SS $5B57
- LiquidiaLQDA $4.94B43
- CosmoCMHC.SW $1.19B37
- Achieve Life SciencesQUIT $663.72M41
- SwedencareSECARE.ST $310.94M52
ETFs that hold Prestige Consumer Healthcare
Held by 13 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.14% | 0.30% | €2.28B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.10% | 0.30% | €185.82M |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.07% | 0.30% | €2.17B |
Show 5 more
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.07% | 0.30% | €4.22B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.06% | 0.30% | €944.34M |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.02% | 0.45% | €1.53B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.01% | 0.43% | €2.48B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.01% | 0.35% | €434.1M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 14 Mar 2025)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.